 Andrew Bubak
Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpesvirus 3, Human | 22 | 2026 | 343 | 5.900 |
Why?
| | Varicella Zoster Virus Infection | 7 | 2026 | 29 | 4.110 |
Why?
| | Herpes Zoster | 13 | 2026 | 319 | 3.880 |
Why?
| | Amyloid beta-Peptides | 7 | 2024 | 246 | 3.020 |
Why?
| | Aggression | 6 | 2020 | 180 | 1.990 |
Why?
| | Virus Activation | 4 | 2026 | 94 | 1.920 |
Why?
| | Serotonin | 6 | 2020 | 298 | 1.860 |
Why?
| | Islet Amyloid Polypeptide | 3 | 2021 | 48 | 1.850 |
Why?
| | Diptera | 5 | 2020 | 30 | 1.760 |
Why?
| | Astrocytes | 3 | 2020 | 228 | 1.500 |
Why?
| | Arteritis | 2 | 2021 | 23 | 1.220 |
Why?
| | Peptide Fragments | 3 | 2024 | 697 | 1.120 |
Why?
| | Herpes Simplex | 2 | 2026 | 99 | 1.100 |
Why?
| | Herpesvirus 1, Human | 2 | 2026 | 84 | 1.080 |
Why?
| | Macaca mulatta | 3 | 2024 | 186 | 0.970 |
Why?
| | Virus Diseases | 4 | 2022 | 217 | 0.950 |
Why?
| | Behavior, Animal | 3 | 2019 | 520 | 0.920 |
Why?
| | Extracellular Vesicles | 2 | 2026 | 171 | 0.890 |
Why?
| | Stroke | 4 | 2023 | 1271 | 0.870 |
Why?
| | Coinfection | 1 | 2026 | 143 | 0.850 |
Why?
| | Neurodegenerative Diseases | 1 | 2026 | 143 | 0.820 |
Why?
| | Cytokines | 3 | 2024 | 2069 | 0.810 |
Why?
| | Antiviral Agents | 5 | 2026 | 769 | 0.790 |
Why?
| | DNA, Viral | 3 | 2024 | 356 | 0.780 |
Why?
| | Substance P | 2 | 2020 | 38 | 0.780 |
Why?
| | Exanthema | 2 | 2022 | 86 | 0.730 |
Why?
| | Octopamine | 3 | 2016 | 9 | 0.700 |
Why?
| | Gene Expression Regulation, Viral | 2 | 2019 | 93 | 0.680 |
Why?
| | Adventitia | 1 | 2021 | 42 | 0.680 |
Why?
| | Temporal Arteries | 1 | 2021 | 45 | 0.670 |
Why?
| | Giant Cell Arteritis | 1 | 2021 | 48 | 0.660 |
Why?
| | Models, Animal | 2 | 2020 | 392 | 0.660 |
Why?
| | Cerebrovascular Disorders | 1 | 2021 | 105 | 0.650 |
Why?
| | Antigens, Viral | 1 | 2021 | 182 | 0.650 |
Why?
| | Antibodies, Viral | 3 | 2024 | 674 | 0.650 |
Why?
| | Amyloid | 1 | 2021 | 96 | 0.630 |
Why?
| | Protein Aggregation, Pathological | 1 | 2020 | 18 | 0.630 |
Why?
| | Receptors, Serotonin | 1 | 2020 | 34 | 0.610 |
Why?
| | Central Nervous System Infections | 1 | 2020 | 35 | 0.610 |
Why?
| | Vascular Remodeling | 1 | 2021 | 209 | 0.590 |
Why?
| | Meningitis | 1 | 2020 | 80 | 0.580 |
Why?
| | Dopamine | 3 | 2016 | 295 | 0.570 |
Why?
| | Receptors, Neurokinin-1 | 1 | 2018 | 8 | 0.560 |
Why?
| | Pseudopodia | 1 | 2018 | 27 | 0.550 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2018 | 117 | 0.540 |
Why?
| | Acyclovir | 3 | 2026 | 98 | 0.540 |
Why?
| | Ants | 1 | 2016 | 25 | 0.490 |
Why?
| | Alzheimer Disease | 1 | 2022 | 630 | 0.470 |
Why?
| | Fibroblasts | 1 | 2021 | 1028 | 0.470 |
Why?
| | Spinal Cord | 1 | 2018 | 382 | 0.460 |
Why?
| | Trigeminal Ganglion | 2 | 2026 | 27 | 0.450 |
Why?
| | Chickenpox | 3 | 2026 | 84 | 0.450 |
Why?
| | MPTP Poisoning | 1 | 2015 | 6 | 0.450 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2015 | 72 | 0.440 |
Why?
| | Dopaminergic Neurons | 1 | 2015 | 68 | 0.420 |
Why?
| | Social Perception | 1 | 2015 | 103 | 0.410 |
Why?
| | Agonistic Behavior | 1 | 2013 | 2 | 0.410 |
Why?
| | Animals | 17 | 2026 | 38106 | 0.400 |
Why?
| | Biogenic Monoamines | 1 | 2013 | 17 | 0.390 |
Why?
| | Varicellovirus | 2 | 2024 | 17 | 0.390 |
Why?
| | Sex Characteristics | 1 | 2019 | 789 | 0.390 |
Why?
| | Brain Chemistry | 1 | 2013 | 120 | 0.380 |
Why?
| | Hippocampus | 1 | 2018 | 973 | 0.370 |
Why?
| | 5-Hydroxytryptophan | 3 | 2019 | 19 | 0.340 |
Why?
| | Herpesviridae Infections | 2 | 2024 | 148 | 0.340 |
Why?
| | Cells, Cultured | 6 | 2021 | 4151 | 0.340 |
Why?
| | Humans | 25 | 2026 | 145785 | 0.300 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 442 | 0.290 |
Why?
| | Virus Latency | 2 | 2026 | 90 | 0.280 |
Why?
| | Male | 14 | 2024 | 73012 | 0.270 |
Why?
| | Gene Expression | 3 | 2020 | 1478 | 0.250 |
Why?
| | 2-Aminopurine | 1 | 2026 | 10 | 0.250 |
Why?
| | Host-Pathogen Interactions | 2 | 2020 | 361 | 0.240 |
Why?
| | Foscarnet | 1 | 2026 | 22 | 0.240 |
Why?
| | Valine | 1 | 2026 | 83 | 0.240 |
Why?
| | Monkey Diseases | 1 | 2024 | 25 | 0.200 |
Why?
| | Trigeminal Neuralgia | 1 | 2024 | 15 | 0.200 |
Why?
| | Tyramine | 2 | 2013 | 8 | 0.200 |
Why?
| | Neuralgia, Postherpetic | 1 | 2024 | 40 | 0.200 |
Why?
| | Sensory Receptor Cells | 1 | 2024 | 98 | 0.200 |
Why?
| | Immunoglobulin G | 2 | 2024 | 892 | 0.190 |
Why?
| | Presenilin-1 | 1 | 2022 | 34 | 0.190 |
Why?
| | Nerve Block | 1 | 2024 | 108 | 0.180 |
Why?
| | Azadirachta | 1 | 2022 | 3 | 0.180 |
Why?
| | Microglia | 1 | 2024 | 273 | 0.180 |
Why?
| | Neuralgia | 1 | 2024 | 140 | 0.180 |
Why?
| | Exosomes | 1 | 2023 | 104 | 0.180 |
Why?
| | Inflammation | 3 | 2022 | 2885 | 0.180 |
Why?
| | Viral Proteins | 1 | 2024 | 350 | 0.170 |
Why?
| | Tissue Fixation | 1 | 2021 | 37 | 0.170 |
Why?
| | Neuroblastoma | 1 | 2023 | 174 | 0.170 |
Why?
| | Paraffin Embedding | 1 | 2021 | 33 | 0.170 |
Why?
| | Plasma | 1 | 2023 | 223 | 0.170 |
Why?
| | Olfactory Bulb | 1 | 2022 | 99 | 0.170 |
Why?
| | Formaldehyde | 1 | 2021 | 65 | 0.170 |
Why?
| | Adrenal Glands | 1 | 2021 | 76 | 0.170 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2021 | 11 | 0.160 |
Why?
| | DNA, Complementary | 1 | 2021 | 273 | 0.160 |
Why?
| | Olfactory Receptor Neurons | 1 | 2021 | 42 | 0.160 |
Why?
| | Neuronal Outgrowth | 1 | 2020 | 9 | 0.160 |
Why?
| | TRPM Cation Channels | 1 | 2021 | 74 | 0.160 |
Why?
| | Cell Death | 1 | 2022 | 382 | 0.160 |
Why?
| | Whole-Body Irradiation | 1 | 2020 | 74 | 0.160 |
Why?
| | Cell Movement | 3 | 2019 | 963 | 0.150 |
Why?
| | Intracellular Space | 1 | 2020 | 64 | 0.150 |
Why?
| | Extracellular Space | 1 | 2020 | 117 | 0.150 |
Why?
| | Protein Aggregates | 1 | 2020 | 86 | 0.150 |
Why?
| | Antigens, CD | 2 | 2019 | 558 | 0.150 |
Why?
| | Viral Envelope Proteins | 1 | 2020 | 98 | 0.150 |
Why?
| | Tacrolimus | 1 | 2020 | 196 | 0.150 |
Why?
| | Receptors, Serotonin, 5-HT2 | 1 | 2019 | 3 | 0.150 |
Why?
| | Tachykinins | 1 | 2019 | 9 | 0.150 |
Why?
| | Corneal Keratocytes | 1 | 2019 | 8 | 0.150 |
Why?
| | Behavior Observation Techniques | 1 | 2019 | 10 | 0.150 |
Why?
| | Diabetic Neuropathies | 1 | 2020 | 100 | 0.140 |
Why?
| | Thrombosis | 1 | 2023 | 400 | 0.140 |
Why?
| | Neurokinin-1 Receptor Antagonists | 1 | 2018 | 4 | 0.140 |
Why?
| | Epithelium, Corneal | 1 | 2019 | 41 | 0.140 |
Why?
| | Neuropeptides | 1 | 2019 | 75 | 0.140 |
Why?
| | Spiro Compounds | 1 | 2018 | 17 | 0.140 |
Why?
| | Radiosurgery | 1 | 2022 | 399 | 0.140 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 344 | 0.140 |
Why?
| | Aged | 5 | 2024 | 26217 | 0.140 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2018 | 122 | 0.140 |
Why?
| | Myofibroblasts | 1 | 2019 | 149 | 0.130 |
Why?
| | Female | 8 | 2024 | 79045 | 0.130 |
Why?
| | MicroRNAs | 1 | 2024 | 686 | 0.130 |
Why?
| | Cadherins | 1 | 2019 | 201 | 0.130 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 334 | 0.130 |
Why?
| | Risk | 1 | 2020 | 923 | 0.130 |
Why?
| | Motor Neurons | 1 | 2020 | 236 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 561 | 0.130 |
Why?
| | Multiple Sclerosis | 1 | 2023 | 489 | 0.130 |
Why?
| | Aortic Diseases | 1 | 2018 | 125 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 1 | 2020 | 484 | 0.120 |
Why?
| | Protein Isoforms | 1 | 2018 | 399 | 0.120 |
Why?
| | Touch | 1 | 2016 | 39 | 0.120 |
Why?
| | Nesting Behavior | 1 | 2016 | 18 | 0.120 |
Why?
| | B7-H1 Antigen | 1 | 2019 | 244 | 0.120 |
Why?
| | Neurotransmitter Agents | 1 | 2016 | 84 | 0.120 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 638 | 0.120 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5995 | 0.120 |
Why?
| | Proteomics | 1 | 2022 | 1188 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 838 | 0.110 |
Why?
| | Interleukin-6 | 1 | 2019 | 780 | 0.110 |
Why?
| | Caudate Nucleus | 1 | 2015 | 22 | 0.110 |
Why?
| | Transcriptome | 1 | 2021 | 1042 | 0.110 |
Why?
| | Body Size | 1 | 2015 | 88 | 0.110 |
Why?
| | Oxygen | 1 | 2020 | 981 | 0.110 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1777 | 0.100 |
Why?
| | RNA, Messenger | 2 | 2020 | 2805 | 0.100 |
Why?
| | Flight, Animal | 1 | 2013 | 23 | 0.100 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 2013 | 24 | 0.100 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2013 | 46 | 0.100 |
Why?
| | Competitive Behavior | 1 | 2013 | 43 | 0.100 |
Why?
| | Risk Assessment | 1 | 2023 | 3752 | 0.100 |
Why?
| | Olfactory Mucosa | 2 | 2024 | 40 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 923 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2601 | 0.090 |
Why?
| | Transcription, Genetic | 1 | 2019 | 1454 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2020 | 3634 | 0.090 |
Why?
| | Data Interpretation, Statistical | 1 | 2013 | 368 | 0.090 |
Why?
| | Middle Aged | 3 | 2024 | 36309 | 0.080 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4568 | 0.080 |
Why?
| | Brain | 2 | 2024 | 2969 | 0.070 |
Why?
| | Biomarkers | 1 | 2020 | 4302 | 0.070 |
Why?
| | Virus Replication | 2 | 2022 | 521 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2020 | 8347 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2933 | 0.060 |
Why?
| | Mice | 4 | 2024 | 18358 | 0.050 |
Why?
| | Risk Factors | 1 | 2018 | 10919 | 0.050 |
Why?
| | Apoptosis | 2 | 2023 | 2445 | 0.050 |
Why?
| | Limonins | 1 | 2022 | 2 | 0.050 |
Why?
| | Plant Bark | 1 | 2022 | 11 | 0.050 |
Why?
| | Central Nervous System | 1 | 2024 | 282 | 0.040 |
Why?
| | Adrenal Cortex | 1 | 2022 | 33 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2022 | 172 | 0.040 |
Why?
| | Macaca fascicularis | 1 | 2021 | 70 | 0.040 |
Why?
| | Histological Techniques | 1 | 2021 | 39 | 0.040 |
Why?
| | Adult | 2 | 2024 | 40882 | 0.040 |
Why?
| | Cerebral Arteries | 1 | 2021 | 59 | 0.040 |
Why?
| | Interleukins | 1 | 2022 | 248 | 0.040 |
Why?
| | Plant Extracts | 1 | 2022 | 188 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 314 | 0.040 |
Why?
| | Claudin-1 | 1 | 2019 | 17 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 467 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2019 | 112 | 0.040 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2019 | 14 | 0.040 |
Why?
| | Cell Hypoxia | 1 | 2020 | 247 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2019 | 28 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2019 | 45 | 0.040 |
Why?
| | Electrochemical Techniques | 1 | 2019 | 55 | 0.030 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 105 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2019 | 247 | 0.030 |
Why?
| | Matrix Metalloproteinases | 1 | 2019 | 95 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2020 | 263 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2022 | 1217 | 0.030 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2020 | 273 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 266 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2019 | 979 | 0.030 |
Why?
| | Action Potentials | 1 | 2020 | 502 | 0.030 |
Why?
| | Macrophages | 1 | 2024 | 1507 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2019 | 574 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2192 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1505 | 0.030 |
Why?
| | Cell Line | 1 | 2020 | 2823 | 0.030 |
Why?
| | DNA | 1 | 2021 | 1437 | 0.030 |
Why?
| | Mitochondria | 1 | 2020 | 994 | 0.020 |
Why?
| | RNA | 1 | 2019 | 912 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2019 | 1146 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2019 | 2514 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2023 | 6465 | 0.020 |
Why?
| | Infant | 1 | 2024 | 10091 | 0.020 |
Why?
| | Child, Preschool | 1 | 2024 | 11868 | 0.020 |
Why?
| | Young Adult | 1 | 2024 | 14254 | 0.020 |
Why?
| | Adolescent | 1 | 2024 | 22577 | 0.010 |
Why?
| | Child | 1 | 2024 | 22740 | 0.010 |
Why?
|
|
Bubak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|